dynein axonemal heavy chain 8Genealiases: ATPase · SPGF46 · hdhc9
Q-omics provides the consensus-scored DNAH8 profile across patient tissues and cancer cell-line models. DNAH8 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DNAH8 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, DNAH8 RNA expression shows 13,245 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, LIHC, and TGCT as cancer lineages where DNAH8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAH8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAH8 survival associations across molecular data types. DNAH8 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAH8 RNA expression–survival associations across cancer types. High DNAH8 expression shows unfavorable associations in ACC, KIRP and KIRC, but favorable associations in BLCA, HNSC and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for DNAH8 RNA expression.
This table summarizes DNAH8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNAH8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAH8 shows lower tumor expression in KIRP, KICH, THCA and LUAD and higher tumor expression in LIHC and BRCA. The LIHC box plot shows higher DNAH8 RNA expression in tumor versus normal tissue (log2 FC = +0.037, t-test p < 0.001).
This table shows molecular features associated with DNAH8 in patient tissues and cancer cell lines. In patient samples, DNAH8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAH8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
